{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:47Z","timestamp":1792521467363,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005703","name":"Akdeniz \u00dcniversitesi","doi-asserted-by":"publisher","award":["2014.02.0122.002"],"award-info":[{"award-number":["2014.02.0122.002"]}],"id":[{"id":"10.13039\/501100005703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejphar.2021.174333","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T23:30:21Z","timestamp":1626478221000},"page":"174333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Functional effects of visfatin in isolated rat mesenteric small resistance arteries"],"prefix":"10.1016","volume":"908","author":[{"given":"Esra","family":"Akcabag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-013X","authenticated-orcid":false,"given":"Ikbal Ozen","family":"Kucukcetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbahar","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebahat","family":"Ozdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-5209","authenticated-orcid":false,"given":"Sadi S.","family":"Ozdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174333_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cvr\/cvm111","article-title":"Visfatin induces human endothelial VEGF and MMP-2\/9 production via MAPK and PI3K\/Akt signalling pathways: novel insights into visfatin-induced angiogenesis","volume":"78","author":"Adya","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174333_bib2","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2337\/diabetes.54.10.2911","article-title":"Plasma visfatin concentrations and fat depot-specific mRNA expression in humans","volume":"54","author":"Berndt","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2021.174333_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.1201","article-title":"Visfatin in overweight\/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review","volume":"27","author":"Chang","year":"2011","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.ejphar.2021.174333_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/jc.2005-1475","article-title":"Elevated plasma level of visfatin\/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus","volume":"91","author":"Chen","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2021.174333_bib5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0022-3565(24)36926-5","article-title":"Role of nitric oxide and Ca++-dependent K+ channels in mediating heterogeneous microvascular responses to acetylcholine in different vascular beds","volume":"282","author":"Clark","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174333_bib6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.106.665893","article-title":"Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization","volume":"115","author":"Dahl","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174333_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112444","article-title":"Visfatin: a possible role in cardiovasculo-metabolic disorders","volume":"9","author":"Dakroub","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2021.174333_bib8","first-page":"H1153","article-title":"Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals","volume":"266","author":"Diederich","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2021.174333_bib9","doi-asserted-by":"crossref","first-page":"155193","DOI":"10.1016\/j.cyto.2020.155193","article-title":"The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents","volume":"134","author":"Ezzati-Mobaser","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2021.174333_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157016110790226679","article-title":"Visfatin\/PBEF and atherosclerosis-related diseases","volume":"8","author":"Filippatos","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174333_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00424-010-0808-2","article-title":"Nitric oxide and oxidative stress in vascular disease","volume":"459","author":"F\u00f6rstermann","year":"2010","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.ejphar.2021.174333_bib12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: from marvel to menace","volume":"113","author":"F\u00f6rstermann","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174333_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin","volume":"307","author":"Fukuhara","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2021.174333_bib14","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/1078-0432.CCR-14-0624","article-title":"On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells","volume":"20","author":"Gehrke","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejphar.2021.174333_bib15","first-page":"861496","article-title":"Associations between tissue visfatin\/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects","author":"Goktas","year":"2013","journal-title":"Mediators Inflamm. 2013"},{"key":"10.1016\/j.ejphar.2021.174333_bib16","first-page":"505","article-title":"Adipocytokines - novel link between inflammation and vascular function?","volume":"57","author":"Guzik","year":"2006","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174333_bib17","first-page":"141","article-title":"Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance. Egypt","volume":"25","author":"Hetta","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2021.174333_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/ajh\/hpv132","article-title":"Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients","volume":"29","author":"Hsu","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2021.174333_bib19","first-page":"H952","article-title":"Comparison of acetylcholine-dependent relaxation in large and small arteries of rat mesenteric vascular bed","volume":"266","author":"Hwa","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2021.174333_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3329\/akmmcj.v9i2.39201","article-title":"Serum visfatin levels estimated in overweight individuals","volume":"9","author":"Kabir","year":"2018","journal-title":"Anwer Khan Mod. Med. Coll. J."},{"key":"10.1016\/j.ejphar.2021.174333_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2009.11.011","article-title":"The autocrine and paracrine roles of adipokines","volume":"318","author":"Karastergiou","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174333_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2007.03.105","article-title":"Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1\/2","volume":"357","author":"Kim","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2021.174333_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1566524018666180705114131","article-title":"Adipokine visfatin's role in pathogenesis of diabesity and related metabolic derangements","volume":"18","author":"Kumari","year":"2018","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejphar.2021.174333_bib24","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar4467","article-title":"Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis","volume":"16","author":"Laiguillon","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejphar.2021.174333_bib25","doi-asserted-by":"crossref","first-page":"H2031","DOI":"10.1152\/ajpheart.01058.2004","article-title":"Adipokines: molecular links between obesity and atheroslcerosis","volume":"288","author":"Lau","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2021.174333_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03453.x","article-title":"Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans","volume":"71","author":"Liu","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174333_bib27","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2337\/db06-0259","article-title":"Serum visfatin increases with progressive beta-cell deterioration","volume":"55","author":"L\u00f3pez-Bermejo","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2021.174333_bib28","first-page":"E1440","article-title":"Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis","volume":"296","author":"Lovren","year":"2009","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.ejphar.2021.174333_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.174333_bib30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/SLA.0000000000000329","article-title":"FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice via NF-\u03baB pathway","volume":"259","author":"Matsuda","year":"2014","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejphar.2021.174333_bib31","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.2174\/15680266113136660208","article-title":"Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders","volume":"13","author":"Montecucco","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174333_bib32","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.178.3.1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties","volume":"178","author":"Moschen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2021.174333_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1152\/physrev.1990.70.4.921","article-title":"Structure and function of small arteries","volume":"70","author":"Mulvany","year":"1990","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2021.174333_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.RES.41.1.19","article-title":"Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats","volume":"41","author":"Mulvany","year":"1977","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174333_bib35","first-page":"308","article-title":"Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice","volume":"111","author":"Nencioni","year":"2014","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2021.174333_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4155\/fmc.12.34","article-title":"PBEF\/NAMPT\/visfatin: a promising drug target for treating rheumatoid arthritis?","volume":"4","author":"Nowell","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174333_bib37","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.bjp.0701749","article-title":"Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats","volume":"123","author":"Rodr\u00edguez-Ma\u00f1as","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174333_bib38","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00125-009-1509-2","article-title":"Extracellular PBEF\/NAMPT\/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity","volume":"52","author":"Romacho","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2021.174333_bib39","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L","article-title":"Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis","volume":"32","author":"Rongvaux","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2021.174333_bib40","first-page":"1431","article-title":"Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor","volume":"14","author":"Samal","year":"1994","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174333_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.metabol.2006.12.005","article-title":"Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians","volume":"56","author":"Sandeep","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174333_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5551\/jat.1735","article-title":"Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis","volume":"17","author":"Spiroglou","year":"2010","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.ejphar.2021.174333_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.mol.0000217893.77746.4b","article-title":"An update on visfatin\/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity","volume":"17","author":"Stephens","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejphar.2021.174333_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.metabol.2006.12.001","article-title":"Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus","volume":"56","author":"Takebayashi","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174333_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.peptides.2018.01.005","article-title":"Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus","volume":"101","author":"Tsiotra","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2021.174333_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027299","article-title":"Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity","volume":"6","author":"Vallejo","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2021.174333_bib47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/cvr\/cvn288","article-title":"Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide","volume":"81","author":"Wang","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174333_bib48","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ajpath.2014.01.032","article-title":"Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin","volume":"184","author":"Xia","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2021.174333_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2009.04.074","article-title":"Visfatin causes endothelium-dependent relaxation in isolated blood vessels","volume":"383","author":"Yamawaki","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2021.174333_bib50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/ndt\/gfm727","article-title":"Serum visfatin concentration and endothelial dysfunction in chronic kidney disease","volume":"23","author":"Yilmaz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2021.174333_bib51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1399-0012.2008.00921.x","article-title":"Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin\/NAMPT. A novel marker of endothelial damage?","volume":"23","author":"Yilmaz","year":"2009","journal-title":"Clin. Transplant."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921004866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921004866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:54:36Z","timestamp":1757976876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921004866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":51,"alternative-id":["S0014299921004866"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174333","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional effects of visfatin in isolated rat mesenteric small resistance arteries","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174333"}}